Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest Medicare Data Suggests No Heightened Death Risk For Paclitaxel-Coated Devices

Executive Summary

A large study of US Medicare patients treated with either drug-coated stents, balloons or other equivalent devices shows a similar morbidity rate in both groups, further contradicting a 2018 literature review that warned of higher death rates in patients treated with paclitaxel-coated devices.

You may also be interested in...



FDA-Guided Study Finds No Paclitaxel Death Risk In Medicare Patients

The SAFE-PAD study, which looked at data from more than 168,000 Medicare beneficiaries, found a slightly lower death rate in patients treated with drug-coated balloons and stents than those who were not.

For Second Time This Month, Medtronic Announces Class I FDA Recall Related To HeartWare System Component

Medtronic, Baxter and BD are all facing recalls, with Medtronic finding yet another issue with HeartWare HVAD systems. Separately, the FDA put a Baxter respiratory device recall into Class I, and BD announced a recall on intraosseous devices.

FDA Plans Meeting On Pulse Oximeter Accuracy

US regulators plan to hold a public meeting later this year to address concerns the devices are less accurate for people with darker skin tones.

Topics

Latest News
UsernamePublicRestriction

Register

MT145445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel